All In Biotech

Drug Trial Radar · NCT07807449

Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older

A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Jan 22, 2027

Study completion Jan 22, 2029

Sponsor

Sponsor type
Industry
Collaborators
Jiangsu Province Centers for Disease Control and Prevention
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

  • Recombinant RSV Vaccine (CHO Cell)Biological

    0.4 mL per dose

  • Recombinant RSV Vaccine (CHO Cell)Biological

    0.8 mL per dose

  • Adjuvant SuspensionBiological

    0.9 mL per dose

  • Recombinant RSV Vaccine (CHO Cell) with Adjuvant SuspensionBiological

    0.9 mL per dose

  • Saline solutionBiological

    0.9 mL per dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of immediate adverse eventsTime frame: Within 30 minutes after vaccination
  2. Incidence of solicited AEsTime frame: Within 0-14 days after vaccination
  3. Incidence of unsolicited AEsTime frame: Within 30 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yixing People's Hospital

    Yixing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.